Cardiac complications after haploidentical HLA-mismatched hematopoietic stem cell transplantation using in vivo alemtuzumab

scientific article published on 01 November 2005

Cardiac complications after haploidentical HLA-mismatched hematopoietic stem cell transplantation using in vivo alemtuzumab is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1004654264
P356DOI10.1038/SJ.BMT.1705145
P698PubMed publication ID16113661

P50authorKoji IzutsuQ73006741
P2093author name stringS Ogawa
H Hirai
T Watanabe
M Kurokawa
S Chiba
Y Kanda
K Oshima
T Motokura
M Sakata-Yanagimoto
E Shoda
Y Asano-Mori
P2860cites workHigh remission rate in T-cell prolymphocytic leukemia with CAMPATH-1HQ28215194
Phase II study of alemtuzumab in chronic lymphoproliferative disordersQ33349421
Pathophysiological role of cytokines in congestive heart failureQ34131932
Engraftment syndrome following hematopoietic stem cell transplantationQ34298239
The CD52 antigen and development of the CAMPATH antibodiesQ34780507
Inflammatory mediators and the failing heart: past, present, and the foreseeable futureQ35011415
Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndromeQ35741601
Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimenQ43863962
BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients.Q44582243
Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioningQ44826910
Early and late elevation of plasma atrial and brain natriuretic peptides in patients after bone marrow transplantationQ48788011
Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: Limited efficacy of graft-versus-tumor activityQ61651657
Regimen-related toxicity in patients undergoing bone marrow transplantationQ70215525
Treatment of T-cell prolymphocytic leukemia with human CD52 antibodyQ73494835
Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumabQ73888073
Predictors for severe cardiac complications after hematopoietic stem cell transplantationQ79872383
In vivo alemtuzumab enables haploidentical human leukocyte antigen-mismatched hematopoietic stem-cell transplantation without ex vivo graft manipulationQ81778094
P433issue9
P921main subjectstem cell transplantationQ65592366
P304page(s)821-824
P577publication date2005-11-01
P1433published inBone Marrow TransplantationQ4941523
P1476titleCardiac complications after haploidentical HLA-mismatched hematopoietic stem cell transplantation using in vivo alemtuzumab
P478volume36

Reverse relations

cites work (P2860)
Q38750270Cardiomyopathy in patients after posttransplant cyclophosphamide-based hematopoietic cell transplantation.
Q40171238Diffuse Alveolar haemorrhage: a fatal complication after alemtuzumab induction therapy in renal transplantation.

Search more.